Aurora Research Institute

Presentation Notes

Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.


Conclusions: Using patients' clinical and genetic information in warfarin therapy protocols can significantly reduce IS [ischemic stroke] and ICH [intracranial hemorrhage] related healthcare expenditures over a five-year period. The PG-protocol 3 generates the greatest total average savings at $78.98 per patient over five-years. The clinical and PG-protocols [pharmacogenomic-based protocols] only modestly reduce the absolute even rate for IS and ICH when compared to the current AHC 'Best-Practice' warfarin therapy protocol. However, with an average of 3,000 patients annually initiating warfarin for AF and the large acute care and five-year costs associated with IS and ICH, even incremental reductions in adverse events through PG-guided care produce savings. Given the substantial reduction in costs associated with genotyping patients, $78.98 per patient is likely an achievable price point at which using a PG-protocol would result in a neutral cost difference. Next steps include developing expense estimates to including PG-guidance into warfarin therapy work flow.

Document Type





To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.